Heidelberg Pharma AG Return on Equity

Heidelberg Pharma AG (HPHA.DE) currently reports a ROE of 232.8%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Heidelberg Pharma AG's ROE history and peer comparisons.

Heidelberg Pharma AG's ROE of 232.8% is higher than the Healthcare sector average of -75.59%. That is roughly 408.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Heidelberg Pharma AG's current 232.8% should be judged against Healthcare norms (sector average: -75.59%) and against HPHA.DE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 232.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Heidelberg Pharma AG, and consider following HPHA.DE for alerts when major investors trade the stock.

Heidelberg Pharma AG is classified in the Healthcare sector. On ROE, it currently shows 232.8% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HPHA.DE with unrelated industries.